Do you ever initiate on degarelix and then switch to leuprolide for patients with prostate cancer and cardiac risk factors receiving ADT?

Topics: Radiation Oncology • Genitourinary Cancers • Prostate Cancer • Medical Oncology • Cardiology • Cardio-Oncology

If so, how long are they on degarelix before the switch?

Answer from: Medical Oncologist at Community Practice

I do not believe that there is a major differential in cardiotoxicity between LHRH antagonists and agonists. The key issue is metabolic syndrome associated with long-term androgen deprivation. Randomized trials have not shown convincing evidence of a difference in cardiotoxicity between agonists and...

Comments

Medical Oncologist at Duke University School of Medicine
I agree which is why we are conducting a randomize...

Radiation Oncologist at American Cancer Center
Good information

Radiation Oncologist at Sutter Health Sacramento
I understand the PRONOUNCE trial, comparing Leupro...

Medical Oncologist at Veterans Administration Health Care Center
I suggest that you reread the trial and consider w...

Medical Oncologist at Stanford School of Medicine
Do you give run-in of peripheral blockade for all ...

Medical Oncologist at University of Mississippi Medical Center
No. My general approach to peripheral blockade for...

Medical Oncologist at Veterans Administration Health Care Center
I usually use a run-in period with a peripheral bl...

Answer from: Radiation Oncologist at Academic Institution

Regardless of the cardiac history, degarelix if covered by insurance because of the ease of discontinuing the ADT. Otherwise leuprolide or equivalent.

Related Questions